Indication

Oligodendroglioma

Oligodendroglioma is a primary, diffusely infiltrating central nervous system neoplasm that arises from oligodendroglial lineage cells within the brain, most commonly affecting the cerebral hemispheres—particularly the frontal and temporal lobes—in young to middle-aged adults. Read more about Oligodendroglioma

1 drugs 1 manufacturers

Advertisement

Drugs that treat it

Common Oligodendroglioma therapies.

Showing 1–1 of 1 drugs

Filter & compare in the drug finder →Opens the drug finder with Oligodendroglioma preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Oligodendroglioma.

Oligodendroglioma is a primary, diffusely infiltrating central nervous system neoplasm that arises from oligodendroglial lineage cells within the brain, most commonly affecting the cerebral hemispheres—particularly the frontal and temporal lobes—in young to middle-aged adults.

Under current World Health Organization classification criteria, it is defined pathologically by the mandatory co-occurrence of an isocitrate dehydrogenase (*IDH1* or *IDH2*) mutation and complete concurrent deletion of chromosome arms 1p and 19q (1p/19q codeletion).

Classified as either WHO grade 2 (low grade) or grade 3 (anaplastic), these tumors characteristically present with seizures, headaches, or focal neurologic deficits, exhibiting a classical "fried egg" cytomorphology on histology.

Personalize your experience

Follow Oligodendroglioma and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it